FULC

Fulcrum Therapeutics, Inc. FULC

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,179 of 2,719

Why it scores 33Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Net income

$-26.18M

Quarter to Jun 30

Free cash flow

$-16.15M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$291.30M total
BlackRock, Inc.
$32.30M+63.7%
EcoR1 Capital, LLC
$23.97MNew
TANG CAPITAL MANAGEMENT LLC
$23.87MNew
Nantahala Capital Management, LLC
$20.04M+79.5%
SUVRETTA CAPITAL MANAGEMENT, LLC
$13.47M-43.9%
D. E. Shaw & Co., Inc.
$11.14M+87.5%
CITADEL ADVISORS LLC
$9.90M+109.2%
VANGUARD CAPITAL MANAGEMENT LLC
$9.87M+0.2%
JANE STREET GROUP, LLC
$8.12M+614.4%
STATE STREET CORP
$7.46M+31.4%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$7.32M+400.0%
GSK plc
$6.54M0.0%
Qube Research & Technologies Ltd
$6.40M+79.4%
RENAISSANCE TECHNOLOGIES LLC
$6.03MNew
ADAR1 Capital Management, LLC
$5.73M+1098.7%
MILLENNIUM MANAGEMENT LLC
$5.44M+316.8%
GEODE CAPITAL MANAGEMENT, LLC
$5.24M-3.7%
MARSHALL WACE, LLP
$4.97MNew
UBS Group AG
$4.59M+297.8%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$4.32M+1065.4%
AQR CAPITAL MANAGEMENT LLC
$4.04M+103.1%
GOLDMAN SACHS GROUP INC
$4.01M+91.4%
Ikarian Capital, LLC
$3.84M0.0%
BANK OF AMERICA CORP /DE/
$3.82M+724.1%
ACADIAN ASSET MANAGEMENT LLC
$3.79M+42.8%
See all 155 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/FULC

Earnings Per Share

13fpro.ai/company/FULC

Loading ratio trend…

FULC key financials by period

Reported revenue, net income and operating margin by fiscal year, from Fulcrum Therapeutics, Inc.'s annual filings on SEC EDGAR.

Fulcrum Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2024$80.0M$-9.7M-27.4%
FY 2023$2.8M$-97.3M—
FY 2022$6.3M$-109.9M—
FY 2021$19.2M$-80.8M—
FY 2020$8.8M$-70.8M—
Source: FULC filings on SEC EDGAR →

FULC insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Fulcrum Therapeutics, Inc. (FULC): stock profile, AI score and financials

Fulcrum Therapeutics, Inc. (FULC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FULC at 32.9/100 on a composite quality score built from its SEC filings, placing it at rank #2,179 of 2,719 stocks — the bottom half of the AI-ranked universe. FULC scores in the top quartile across revenue growth (99.7), institutional flow (83.1). Areas of concern include free cash flow (6.8) and profitability (7.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Fulcrum Therapeutics, Inc. reports net income of $-26.2M, free cash flow of $-16.1M. Top institutional holders of FULC by reported 13-F value include BlackRock, EcoR1 Capital, TANG CAPITAL MANAGEMENT, based on the most recent SEC filings. FULC trades on the Nasdaq exchange and files with the SEC under CIK 1680581. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FULC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Fulcrum Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1680581 →